Cas:113558-94-4 N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide manufacturer & supplier

Chemical Name:N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide

CAS.NO:113558-94-4

Synonyms:1-acetyl-4-(4-methylsulfonylaminobenzoyl)piperidine;1-acetyl-4-(4-amino-2-methylphenyl)-piperazine;4-(4-ACETYL-PIPERAZIN-1-YL)-2-METHYLANILINE;Ethanone,1-[4-(4-amino-2-methylphenyl)-1-piperazinyl]

Molecular Formula:C₁₅H₂₀N₂O₄S

Molecular Weight:324.39500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:91.93000

Exact Mass:324.11400

LogP:2.59100

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-acetyl-4-(4-methylsulfonylaminobenzoyl)piperidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethanone,1-[4-(4-amino-2-methylphenyl)-1-piperazinyl] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(4-ACETYL-PIPERAZIN-1-YL)-2-METHYLANILINE Use and application,1-acetyl-4-(4-methylsulfonylaminobenzoyl)piperidine technical grade,usp/ep/jp grade.

Related News: As Reuters reported last month, Lilly tapped the Washington D.C. law firm Covington & Burling LLP to investigate the alleged alterations, which the employees said were meant to downplay serious quality control problems at the plant producing the drugmaker’s COVID-19 antibody treatment. N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide manufacturer Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide supplier The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide vendor We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. N-{4-[(1-Acetyl-4-piperidinyl)carbonyl]phenyl}methanesulfonamide factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.